Show Summary Details
Page of

Managing the Patient with Multidrug-Resistant HIV 

Managing the Patient with Multidrug-Resistant HIV
Managing the Patient with Multidrug-Resistant HIV

Ye Thu

and Naiel Nassar

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 01 October 2020

During approximately the past 15 years, HIV infection has been transformed into a chronic manageable disease primarily due to the effectiveness of antiretroviral therapy. Treatment guidelines emphasize the need for at least two or preferably three fully active medications in the salvage regimens of patients experiencing virologic failure. The new regimen should be started with as little interruption as possible because the structured interruption of treatment in patient with multidrug-resistant HIV infection is associated with greater progression of the disease. The new pharmacokinetic enhancer, cobicistat, is available as a fixed-dose combination product with antiretroviral medication that allows the treatment to be simplified and reduces the pill burden.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.